Retatrutide Clinical Trials Tracker
A live tracker of all 33 retatrutide studies on ClinicalTrials.gov: phase, status, enrollment, comparator, estimated readout dates and what each trial found.
Registry data pulled Oct 31, 2026 from ClinicalTrials.gov. Our readout notes come from Lilly releases and journal papers.
Readout calendar
Primary completion dates still marked as estimates, soonest first. They are registry estimates, not Lilly announcements, and the record often lags the real date.
- Oct 2026Registry estimateTRANSCEND-T2D-3Type 2 diabetes, Phase 3, active, not recruiting. Compared with placebo. 320 planned.
- Nov 2026Registry estimateTRIUMPH-5Obesity or overweight, Phase 3, active, not recruiting. Compared with tirzepatide. 800 planned.
- Jan 2027Registry estimateNCT06982859Type 2 diabetes, Phase 1, active, not recruiting. Compared with semaglutide, placebo. 95 planned.
- Mar 14, 2027Registry estimateGZBFObesity or overweight, Phase 2, recruiting. 300 planned.
- Jul 2027Registry estimateTRIUMPH-8Obesity or overweight, Phase 3, active, not recruiting. Compared with placebo. 250 planned.
- Sep 2027Registry estimateTRIUMPH-7Obesity or overweight, Phase 3, active, not recruiting. Compared with placebo. 586 planned.
- Apr 2028Registry estimateTRIUMPH-6Obesity or overweight, Phase 3, active, not recruiting. Compared with placebo. 643 planned.
- Oct 2028Registry estimateTRIUMPH-9Obesity or overweight, Phase 3, active, not recruiting. 600 planned.
- Feb 2029Registry estimateTRIUMPH-OutcomesHeart or kidney disease, Phase 3, active, not recruiting. Compared with placebo. 10,000 planned.
- Aug 2030Registry estimateSYNERGY-OutcomesFatty liver (MASLD), Phase 3, recruiting. Compared with placebo. 4,500 planned.
Showing 33 of 33 studies
| Compared with | Registry results | Our readout notes | ||||||
|---|---|---|---|---|---|---|---|---|
| Expanded access | Available | Obesity or overweight | Not listed | Not listed | Not applicable | None posted | Not reported yet | |
| Phase 3 | Recruiting | Fatty liver (MASLD) | 4,500estimated | Aug 2030registry estimate | Placebo | None posted | Not reported yet | |
| Phase 3 | Active, not recruiting | Heart or kidney disease | 10,000estimated | Feb 2029registry estimate | Placebo | None posted | Not reported yet | |
| Phase 3 | Active, not recruiting | Obesity or overweight | 600estimated | Oct 2028registry estimate | No comparator listed | None posted | Not reported yet | |
| Phase 3 | Active, not recruiting | Obesity or overweight | 643estimated | Apr 2028registry estimate | Placebo | None posted | Not reported yet | |
| Phase 3 | Active, not recruiting | Obesity or overweight | 586estimated | Sep 2027registry estimate | Placebo | None posted | Not reported yet | |
| Phase 3 | Active, not recruiting | Obesity or overweight | 250estimated | Jul 2027registry estimate | Placebo | None posted | Not reported yet | |
| Phase 2 | Recruiting | Obesity or overweight | 300estimated | Mar 14, 2027registry estimate | No comparator listed | None posted | Not reported yet | |
| Phase 1 | Active, not recruiting | Type 2 diabetes | 95estimated | Jan 2027registry estimate | Semaglutide, Placebo | None posted | Not reported yet | |
| Phase 3 | Active, not recruiting | Obesity or overweight | 800estimated | Nov 2026registry estimate | Tirzepatide | None posted | Not reported yet | |
| Phase 3 | Active, not recruiting | Type 2 diabetes | 320estimated | Oct 2026registry estimate | Placebo | None posted | Not reported yet | |
| Phase 3 | Active, not recruiting | Type 2 diabetes | 1,250estimated | Aug 27, 2026actual | Semaglutide | None posted | 12 mg lost 20.9% of body weight against 9.4% on Ozempic 2 mg, and A1C fell 2.2% against 1.8% (efficacy estimand).Reported Oct 28, 2026. Press release only Our page | |
| Phase 3 | Completed | Obesity with type 2 diabetes | 1,152actual | Jun 16, 2026actual | Placebo | None posted | 12 mg lost 20.8% of body weight against 4.0% on placebo (efficacy estimand).Reported Jul 23, 2026. The Lancet 2026;408(10563), Sep 29, 2026 Our page | |
| Phase 1 | Completed | Type 2 diabetes | 80actual | May 4, 2026actual | Placebo | None posted | No readout on our pages yet | |
| Phase 3 | Completed | Obesity with heart disease | 1,946actual | Apr 16, 2026actual | Placebo | None posted | 12 mg lost 22.6% of body weight against 3.2% on placebo (efficacy estimand).Reported Jul 23, 2026. Press release only Our page | |
| Phase 3 | Completed | Obesity with knee osteoarthritis | 2,335actual | Apr 6, 2026actual | Placebo | None posted | 12 mg lost 28.3% of body weight against 2.2% on placebo (efficacy estimand); the NEJM primary analysis is 25.0% against 3.9% (treatment-regimen estimand).Reported May 21, 2026. New England Journal of Medicine, Sep 29, 2026 Our page | |
| Phase 3 | Completed | Type 2 diabetes | 537actual | Jan 22, 2026actual | Placebo | None posted | At 40 weeks A1C fell 2.0% on 9 mg and 1.9% on 12 mg, against 0.8% on placebo (efficacy estimand).Reported Mar 19, 2026. The Lancet 2026;407(10546), Jun 6, 2026 Our page | |
| Phase 3 | Completed | Obesity or overweight | 445actual | Nov 14, 2025actual | Placebo | None posted | 12 mg lost 28.7% of body weight against 2.1% on placebo (efficacy estimand).Reported Dec 11, 2025. Press release only | |
| Phase 2 | Completed | Obesity with kidney disease | 146actual | Oct 1, 2025actual | Placebo | None posted | No readout on our pages yet | |
| Phase 1 | Completed | Obesity or overweight | 85actual | Aug 26, 2025actual | Placebo | None posted | No readout on our pages yet | |
| Phase 1 | Completed | Healthy volunteers | 30actual | Apr 15, 2025actual | No comparator listed | None posted | No readout on our pages yet | |
| Phase 1 | Completed | Healthy volunteers | 43actual | Mar 2, 2025actual | No comparator listed | None posted | No readout on our pages yet | |
| Phase 1 | Completed | Healthy volunteers | 85actual | Jul 25, 2024actual | No comparator listed | None posted | No readout on our pages yet | |
| Phase 1 | Completed | Obesity or overweight | 46actual | Jul 11, 2024actual | No comparator listed | None posted | No readout on our pages yet | |
| Phase 1 | Completed | Healthy volunteers | 57actual | Feb 8, 2024actual | Reference | None posted | No readout on our pages yet | |
| Phase 1 | Completed | Healthy volunteers | 29actual | Sep 5, 2023actual | No comparator listed | None posted | No readout on our pages yet | |
| Phase 1 | Completed | Obesity or overweight | 32actual | Jul 27, 2023actual | Placebo | None posted | No readout on our pages yet | |
| Phase 1 | Completed | Obesity or overweight | 32actual | Feb 24, 2023actual | No comparator listed | None posted | No readout on our pages yet | |
| Phase 2 | Completed | Type 2 diabetes | 281actual | Jul 8, 2022actual | Dulaglutide, Placebo | Posted | At 24 weeks A1C fell 2.02% on 12 mg, against 0.01% on placebo and 1.41% on dulaglutide.The Lancet 2023;402(10401), Jun 26, 2023 | |
| Phase 1 | Completed | Type 2 diabetes | 64actual | Jun 23, 2022actual | Placebo | None posted | No readout on our pages yet | |
| Phase 2 | Completed | Obesity or overweight | 338actual | May 16, 2022actual | Placebo | Posted | At 48 weeks the 12 mg group lost 24.2% of body weight against 2.1% on placebo.New England Journal of Medicine 2023;389(6), Jun 26, 2023 | |
| Phase 1 | Completed | Type 2 diabetes | 72actual | Dec 28, 2020actual | Dulaglutide, Placebo | None posted | No readout on our pages yet | |
| Phase 1 | Completed | Healthy volunteers | 45actual | Jul 25, 2019actual | Placebo | None posted | No readout on our pages yet |
What the tracker covers
It lists every study on ClinicalTrials.gov with retatrutide as an intervention: 33 records when we last pulled the registry, from the first single-dose safety study to the cardiovascular and liver outcomes trials that run into the 2030s. Six Phase 3 trials have reported so far, and the notes column in the table holds our short summary of each, with the journal paper where one exists. The full write-ups are on the TRIUMPH-4, TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, TRANSCEND-T2D-1 and TRANSCEND-T2D-2 pages, and the Phase 2 page covers the trials before them. TRIUMPH-5, retatrutide against tirzepatide, is the next head-to-head to watch.
How the registry dates work
Sponsors enter these dates themselves, and the registry labels each one as actual or estimated. A primary completion date is when the last person was measured for the main endpoint. It is not the day results come out. Records also lag: an estimate can pass while the study is still listed as active, which the calendar flags. Treat every estimated date as a window, and check the lag Lilly has shown before. It has taken between 27 and 98 days to publish a topline after a primary completion date (our arithmetic from the registry dates and release dates).
Enrollment works the same way. A completed trial shows the number actually enrolled, which can differ from the number Lilly says it randomized. TRIUMPH-1 is 2,335 on the registry and 2,339 in Lilly's release, so the notes use Lilly's figure when we quote one and say so.
How results reach the public
Results arrive in this order, and the registry is usually last. Lilly issues a press release with topline numbers. Detailed results follow at a medical meeting, then a journal paper. The registry's own results section comes after that, and for the Phase 3 trials it is still empty. Only the two Phase 2 trials have results posted there. That is why the table has a "Registry results" column next to our notes: a trial can have reported and still show "None posted".
Where a result has no paper yet, we say "press release only". TRIUMPH-3, TRIUMPH-4 and TRANSCEND-T2D-2 are in that group. A press release is the sponsor's own summary, so read it that way. The estimand matters too, and our notes name it: the efficacy estimand assumes everyone stayed on treatment, while the treatment-regimen estimand counts everyone randomized.
Where to go from here
For what is still running and when each trial should finish, see the ongoing trials page. If you want to take part in one, the near me page lists the open sites. For the combined Phase 3 picture, see the Phase 3 results and the release date page for what the readouts mean for approval.
Frequently asked questions
How many retatrutide clinical trials are there?
ClinicalTrials.gov listed 33 studies with retatrutide as an intervention when we last pulled the registry. 21 are completed, 9 are active but not recruiting, 2 are recruiting and 1 is an expanded access program. Of the Phase 3 trials, six have reported results: TRIUMPH-4, TRANSCEND-T2D-1, TRIUMPH-1, TRIUMPH-2, TRIUMPH-3 and TRANSCEND-T2D-2.
Which retatrutide trial reports next?
The registry's earliest estimated primary completions are TRANSCEND-T2D-3 (October 2026) and TRIUMPH-5, retatrutide against tirzepatide (November 2026). Those are registry estimates, not Lilly announcements. Lilly has taken between 27 and 98 days from a primary completion date to a topline release (our arithmetic from the registry dates and release dates), which points to late November 2026 at the earliest and early March 2027 at the latest.
Why do the trial pages show results that ClinicalTrials.gov doesn't?
Lilly announces topline results in press releases and journals before it posts them on the registry. No Phase 3 trial has results posted on ClinicalTrials.gov yet; only the two Phase 2 trials do. The tracker's 'readout notes' column comes from Lilly's releases and the published papers, and says which of the two a result is from.
Can I still join a retatrutide trial?
Only one Lilly study is recruiting: SYNERGY-Outcomes, a fatty liver study. Every TRIUMPH and TRANSCEND trial is closed to new people. The near-me page lists the open sites and who qualifies.
How often is the tracker updated?
We refresh the registry pull by hand and show its date above the tracker. A new readout only appears in the notes column after we have checked it against the release or the paper.
Sources
- ClinicalTrials.gov API: studies with retatrutide as an intervention. U.S. National Library of Medicine, 2026. clinicaltrials.gov
- What to know about retatrutide. Eli Lilly and Company, 2026. lilly.com
- Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial (TRANSCEND-T2D-2 topline). Eli Lilly and Company via PR Newswire, 2026. prnewswire.com
- Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1; Jastreboff AM et al.). New England Journal of Medicine, 2026. doi.org
- Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2; Bellido V et al.). The Lancet, 2026. doi.org